James M. Eudicone

1.5k total citations
69 papers, 958 citations indexed

About

James M. Eudicone is a scholar working on Psychiatry and Mental health, Pulmonary and Respiratory Medicine and Physiology. According to data from OpenAlex, James M. Eudicone has authored 69 papers receiving a total of 958 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Psychiatry and Mental health, 24 papers in Pulmonary and Respiratory Medicine and 18 papers in Physiology. Recurrent topics in James M. Eudicone's work include Schizophrenia research and treatment (22 papers), Bipolar Disorder and Treatment (19 papers) and Asthma and respiratory diseases (16 papers). James M. Eudicone is often cited by papers focused on Schizophrenia research and treatment (22 papers), Bipolar Disorder and Treatment (19 papers) and Asthma and respiratory diseases (16 papers). James M. Eudicone collaborates with scholars based in United States, Germany and United Kingdom. James M. Eudicone's co-authors include Ronald N. Marcus, Robert D. McQuade, Berit X. Carlson, Ross A. Baker, Quynh-Van Tran, Del D. Miller, Robert Berman, Raymond Mankoski, Trisha Suppes and Richard Whitehead and has published in prestigious journals such as Circulation, Kidney International and Journal of Allergy and Clinical Immunology.

In The Last Decade

James M. Eudicone

57 papers receiving 917 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James M. Eudicone United States	19	643	227	123	116	105	69	958
Pilar Sierra Spain	15	494 0.8×	115 0.5×	90 0.7×	130 1.1×	53 0.5×	56	783
Danielle M. Novick United States	13	777 1.2×	138 0.6×	81 0.7×	348 3.0×	63 0.6×	27	1.0k
Margarida García-García Spain	11	794 1.2×	95 0.4×	195 1.6×	172 1.5×	152 1.4×	16	1.1k
Halldóra Jónsdóttir Norway	19	1.3k 2.0×	118 0.5×	121 1.0×	304 2.6×	111 1.1×	24	1.6k
Estela Salagre Spain	16	649 1.0×	154 0.7×	45 0.4×	186 1.6×	58 0.6×	32	1.0k
Paul Mackin United Kingdom	17	637 1.0×	64 0.3×	248 2.0×	111 1.0×	141 1.3×	34	1.1k
Vicki A. Nejtek United States	15	334 0.5×	72 0.3×	46 0.4×	188 1.6×	135 1.3×	39	929
John Cookson United Kingdom	19	772 1.2×	138 0.6×	102 0.8×	99 0.9×	48 0.5×	62	1.1k
Haranath Parepally United States	16	986 1.5×	107 0.5×	98 0.8×	320 2.8×	100 1.0×	24	1.2k
Manfred Beneke Germany	18	681 1.1×	111 0.5×	344 2.8×	180 1.6×	52 0.5×	34	992

Countries citing papers authored by James M. Eudicone

Since Specialization

Citations

This map shows the geographic impact of James M. Eudicone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James M. Eudicone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James M. Eudicone more than expected).

Fields of papers citing papers by James M. Eudicone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James M. Eudicone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James M. Eudicone. The network helps show where James M. Eudicone may publish in the future.

Co-authorship network of co-authors of James M. Eudicone

This figure shows the co-authorship network connecting the top 25 collaborators of James M. Eudicone. A scholar is included among the top collaborators of James M. Eudicone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James M. Eudicone. James M. Eudicone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gilbert, Ileen, et al.. (2025). Evaluation of a disease-state education program in asthma: Application of the Knowledge-to-Action Framework. Allergy and Asthma Proceedings. 46(2). 126–134.

Chipps, Bradley E., Robert S. Zeiger, David A. Beuther, et al.. (2024). Advancing assessment of asthma control with a composite tool. Annals of Allergy Asthma & Immunology. 133(1). 49–56. 4 indexed citations

Charytan, David M., Wolfgang C. Winkelmayer, Christopher B Granger, et al.. (2024). Effects of dialysate potassium concentration of 3.0 mmol/l with sodium zirconium cyclosilicate on dialysis-free days versus dialysate potassium concentration of 2.0 mmol/l alone on rates of cardiac arrhythmias in hemodialysis patients with hyperkalemia. Kidney International. 107(1). 169–179. 3 indexed citations

McCann, William, Kevin R. Murphy, Robert S. Zeiger, et al.. (2024). Assessing meaningful change in the Asthma Impairment and Risk Questionnaire. Annals of Allergy Asthma & Immunology. 133(2). 152–158.

Chipps, Bradley E., Robert S. Zeiger, David A. Beuther, et al.. (2024). Impact of Utilizing a Composite versus a Symptom-Only Validation Standard in the Development of the Asthma Impairment and Risk Questionnaire. Journal of Asthma and Allergy. Volume 17. 751–756.

Strange, Charlie, et al.. (2024). Validation of the Onset of Effect Questionnaire in Participants With Chronic Obstructive Pulmonary Disease. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 11(4). 359–368. 1 indexed citations

Burton, James O., Alpesh Amin, Cecilia Linde, et al.. (2023). Rationale and design of CONTINUITY: a Phase 4 randomized controlled trial of continued post-discharge sodium zirconium cyclosilicate treatment versus standard of care for hyperkalemia in chronic kidney disease. Clinical Kidney Journal. 16(7). 1160–1169. 2 indexed citations

Reibman, Joan, Bradley E. Chipps, Robert S. Zeiger, et al.. (2023). Relationship Between Asthma Control as Measured by the Asthma Impairment and Risk Questionnaire (AIRQ) and Patient Perception of Disease Status, Health-Related Quality of Life, and Treatment Adherence. Journal of Asthma and Allergy. Volume 16. 59–72. 7 indexed citations

Chipps, Bradley E., Robert S. Zeiger, David A. Beuther, et al.. (2023). The Asthma Impairment and Risk Questionnaire enhances the assessment of asthma control. Annals of Allergy Asthma & Immunology. 131(4). 436–443.e1. 10 indexed citations

10.

Beuther, David A., Kevin R. Murphy, Robert S. Zeiger, et al.. (2022). The Asthma Impairment and Risk Questionnaire (AIRQ) Control Level Predicts Future Risk of Asthma Exacerbations. The Journal of Allergy and Clinical Immunology In Practice. 10(12). 3204–3212.e2. 20 indexed citations

11.

Ostacher, Michael J., Trisha Suppes, Alan C. Swann, et al.. (2015). Patterns of response to aripiprazole, lithium, haloperidol, and placebo across factor scores of mania. International Journal of Bipolar Disorders. 3(1). 11–11. 12 indexed citations

12.

Dunlop, Boadie W., et al.. (2014). How well do clinicians and patients agree on depression treatment outcomes? Implications for personalized medicine. Human Psychopharmacology Clinical and Experimental. 29(6). 528–536. 8 indexed citations

13.

Casey, Dympna, Kimberly K. Laubmeier, James M. Eudicone, et al.. (2014). Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy. International Journal of Clinical Practice. 68(11). 1301–1308. 4 indexed citations

14.

Findling, Robert L., Raymond Mankoski, Robert D. McQuade, et al.. (2014). A Randomized Controlled Trial Investigating the Safety and Efficacy of Aripiprazole in the Long-Term Maintenance Treatment of Pediatric Patients With Irritability Associated With Autistic Disorder. The Journal of Clinical Psychiatry. 75(1). 22–30. 67 indexed citations

15.

Nelson, J. Craig, Zia Ur Rahman, Kimberly K. Laubmeier, et al.. (2014). Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy. CNS Spectrums. 19(6). 528–534. 11 indexed citations

16.

Muzina, David J., et al.. (2011). Adjunctive aripiprazole for depression: predictive value of early assessment.. PubMed. 17(12). 793–801. 10 indexed citations

17.

Weisler, Richard H., Arif Khan, Madhukar H. Trivedi, et al.. (2010). Analysis of Suicidality in Pooled Data From 2 Double-Blind, Placebo-Controlled Aripiprazole Adjunctive Therapy Trials in Major Depressive Disorder. The Journal of Clinical Psychiatry. 72(4). 548–555. 14 indexed citations

18.

Docherty, John P., Ross A. Baker, James M. Eudicone, et al.. (2010). Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia. Schizophrenia Research. 120(1-3). 199–203. 16 indexed citations

19.

Byerly, Matthew, Ronald N. Marcus, Quynh-Van Tran, et al.. (2008). Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: Analysis of a randomized, open-label study. Schizophrenia Research. 107(2-3). 218–222. 71 indexed citations

20.

Suppes, Trisha, et al.. (2007). Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. Journal of Affective Disorders. 107(1-3). 145–154. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact